Natixis Advisors LLC Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Natixis Advisors LLC grew its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 38.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 27,158 shares of the biopharmaceutical company’s stock after purchasing an additional 7,564 shares during the period. Natixis Advisors LLC’s holdings in Xenon Pharmaceuticals were worth $1,069,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. GSA Capital Partners LLP lifted its stake in shares of Xenon Pharmaceuticals by 475.9% in the third quarter. GSA Capital Partners LLP now owns 37,308 shares of the biopharmaceutical company’s stock valued at $1,469,000 after purchasing an additional 30,830 shares during the period. TimesSquare Capital Management LLC increased its holdings in Xenon Pharmaceuticals by 3.2% in the third quarter. TimesSquare Capital Management LLC now owns 778,293 shares of the biopharmaceutical company’s stock valued at $30,641,000 after buying an additional 23,800 shares in the last quarter. Assetmark Inc. lifted its position in shares of Xenon Pharmaceuticals by 7.9% during the 3rd quarter. Assetmark Inc. now owns 19,670 shares of the biopharmaceutical company’s stock valued at $774,000 after acquiring an additional 1,435 shares during the period. Harbor Capital Advisors Inc. lifted its position in shares of Xenon Pharmaceuticals by 99.3% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 48,063 shares of the biopharmaceutical company’s stock valued at $1,892,000 after acquiring an additional 23,947 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its stake in shares of Xenon Pharmaceuticals by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 14,572 shares of the biopharmaceutical company’s stock worth $574,000 after acquiring an additional 5,704 shares in the last quarter. 95.45% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Xenon Pharmaceuticals

In other news, Director Gary Patou sold 4,891 shares of the business’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the sale, the director now owns 23,573 shares of the company’s stock, valued at approximately $968,378.84. The trade was a 17.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 5.52% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on XENE. Raymond James restated an “outperform” rating and issued a $50.00 price target on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada restated an “outperform” rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price target on shares of Xenon Pharmaceuticals in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Finally, Needham & Company LLC reissued a “buy” rating and set a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Eleven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Xenon Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $57.45.

Xenon Pharmaceuticals Trading Up 1.8 %

XENE stock opened at $42.45 on Wednesday. The stock’s 50 day simple moving average is $41.31 and its 200 day simple moving average is $40.20. Xenon Pharmaceuticals Inc. has a 12-month low of $29.00 and a 12-month high of $50.99. The firm has a market cap of $3.24 billion, a P/E ratio of -15.05 and a beta of 1.25.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period last year, the company earned ($0.73) earnings per share. On average, research analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.